Ki67 targeted strategies for cancer therapy

被引:224
|
作者
Yang, C. [1 ]
Zhang, J. [1 ]
Ding, M. [1 ,2 ]
Xu, K. [1 ,2 ]
Li, L. [1 ]
Mao, L. [1 ,2 ]
Zheng, J. [1 ]
机构
[1] Xuzhou Med Univ, Jiangsu Key Lab Biol Canc Therapy, Xuzhou 221002, Peoples R China
[2] Univ Med Coll, Affiliated Hosp, Dept Urinary Surg, Xuzhou 221000, Peoples R China
来源
CLINICAL & TRANSLATIONAL ONCOLOGY | 2018年 / 20卷 / 05期
关键词
Ki67; Gene therapy; Renal cancer; siRNA; Target therapy; Proliferation; PROLIFERATION-ASSOCIATED ANTIGEN; SELECTIVE ADENOVIRUS ONYX-015; SMALL-INTERFERING-RNA; PHASE-I TRIAL; ONCOLYTIC ADENOVIRUS; ANTISENSE OLIGONUCLEOTIDE; PROSTATE-CANCER; BREAST-CANCER; INTRAVENOUS-INFUSION; ANTITUMOR-ACTIVITY;
D O I
10.1007/s12094-017-1774-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ki67 is a well-known proliferation marker for the evaluation of cell proliferation. Numerous studies have indicated that Ki67 index independently predicts cancer progression. Moreover, because Ki67 is highly expressed in malignant cells but almost could not be detected in normal cells, it has become a promising target for cancer therapy. In this review, we summarize recent advances in Ki67 targeted cancer therapy. In particular, we highlight recent development on the exploitation of Ki67 promoter to drive the expression of siRNAs or therapeutic genes in cancer cells specifically. The use of Ki67 as an attractive target opens a new avenue for cancer therapy.
引用
收藏
页码:570 / 575
页数:6
相关论文
共 50 条
  • [1] Ki67 targeted strategies for cancer therapy
    C. Yang
    J. Zhang
    M. Ding
    K. Xu
    L. Li
    L. Mao
    J. Zheng
    Clinical and Translational Oncology, 2018, 20 : 570 - 575
  • [2] Strategies for developing Ki67 as a useful biomarker in breast cancer
    Denkert, Carsten
    Budczies, Jan
    von Minckwitz, Gunter
    Wienert, Stephan
    Loibl, Sibylle
    Klauschen, Frederick
    BREAST, 2015, 24 : S67 - S72
  • [3] Ki67 and Salivary Cancer
    Ben-Izhak, Ofer
    Akrish, Sharon
    Nagler, Rafael M.
    CANCER INVESTIGATION, 2008, 26 (10) : 1015 - 1023
  • [4] Ki67 and proliferation in breast cancer
    Pathmanathan, Nirmala
    Balleine, Rosemary L.
    JOURNAL OF CLINICAL PATHOLOGY, 2013, 66 (06) : 512 - 516
  • [5] Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
    Dowsett, Mitch
    Nielsen, Torsten O.
    A'Hern, Roger
    Bartlett, John
    Coombes, R. Charles
    Cuzick, Jack
    Ellis, Matthew
    Henry, N. Lynn
    Hugh, Judith C.
    Lively, Tracy
    McShane, Lisa
    Paik, Soon
    Penault-Llorca, Frederique
    Prudkin, Ljudmila
    Regan, Meredith
    Salter, Janine
    Sotiriou, Christos
    Smith, Ian E.
    Viale, Giuseppe
    Zujewski, Jo Anne
    Hayes, Daniel F.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (22): : 1656 - 1664
  • [6] Intensity of Ki67 Staining as an Adjuvant Predictor of Response to Neoadjuvant Therapy in Patients with High Ki67
    Zot, Patricija
    Cartagena, Lorraine Colon
    Pillappa, Raghavendra
    Idowu, Michael
    Robila, Valentina
    LABORATORY INVESTIGATION, 2019, 99
  • [7] Intensity of Ki67 Staining as an Adjuvant Predictor of Response to Neoadjuvant Therapy in Patients with High Ki67
    Zot, Patricija
    Cartagena, Lorraine Colon
    Pillappa, Raghavendra
    Idowu, Michael
    Robila, Valentina
    MODERN PATHOLOGY, 2019, 32
  • [8] Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
    Nielsen, Torsten O.
    Leung, Samuel C. Y.
    Rimm, David L.
    Dodson, Andrew
    Acs, Balazs
    Badve, Sunil
    Denkert, Carsten
    Ellis, Matthew J.
    Fineberg, Susan
    Flowers, Margaret
    Kreipe, Hans H.
    Laenkholm, Anne-Vibeke
    Pan, Hongchao
    Penault-Llorca, Friderique M.
    Polley, Mei-Yin
    Salgado, Roberto
    Smith, Ian E.
    Sugie, Tomoharu
    Bartlett, John M. S.
    McShane, Lisa M.
    Dowsett, Mitch
    Hayes, Daniel F.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (07): : 808 - 819
  • [9] The potential of ki67 and p53 assessment in development of individualized targeted therapy in breast cancer patients
    Ormenisan, C.
    Kubik, M.
    Legrand, S.
    Kraemer, D.
    Smotherman, C.
    Masood, S.
    PATHOLOGICA, 2015, 107 (3-4) : 177 - 180
  • [10] Ki67 assessment in breast cancer: an update
    Penault-Llorca, Frederique
    Radosevic-Robin, Nina
    PATHOLOGY, 2017, 49 (02) : 166 - 171